Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) has shared an update.
Mayne Pharma Group Limited reported that all resolutions put to shareholders at its 29 January 2026 Annual General Meeting were approved, including the re-election of directors Ann Custin and David Petrie, adoption of the remuneration report, and the issue of long-term incentive performance rights to the CEO and managing director under the company’s employee equity plan. The strong level of support across the resolutions, despite a notable minority vote against the remuneration report and incentive grant, signals continued shareholder backing for the current board composition and executive incentive structures, reinforcing management’s mandate as the company executes its strategic and operational plans in a competitive pharmaceuticals market.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian-listed specialty pharmaceutical company that develops, manufactures and markets branded and generic medicines, with a focus on complex formulations and regulated markets such as the United States and Australia.
Average Trading Volume: 564,661
Technical Sentiment Signal: Sell
Current Market Cap: A$235.6M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.